Cellyan Biotechnology (HKPD) Total Current Liabilities (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Total Current Liabilities of $3.0 million for Q3 2025, down 16.03% year-over-year from $3.6 million in Q3 2024, and up 3.73% quarter-over-quarter from $2.9 million in Q1 2025.
Cellyan Biotechnology (HKPD) Total Current Liabilities (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Total Current Liabilities data on file, last reported at $3.0 million in Q3 2025.
- Total Current Liabilities for Q3 2025 came in at $3.0 million, down 16.03% year-over-year; the trailing twelve-month figure through Sep 2025 was $3.0 million (down 16.03% YoY), and the FY2025 annual result was $2.9 million, down 8.16% from the prior year.
- Total Current Liabilities rose to $3.0 million in Q3 2025 per HKPD's latest filing, from $2.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $3.6 million in Q3 2024 and troughed at $2.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 12.02 Mn |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | 67.02 Bn |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 56.13 Bn |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | 41.99 Bn |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 3.30 Bn |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | 1.20 Bn |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 37.51 Mn |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | 275.45 Mn |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 34.08 Mn |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 3.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | 2.92 Mn |
| Sep 30, 2024 | 3.60 Mn |
| Mar 31, 2024 | 3.18 Mn |